Company profile
The Cannaisseur Group, Inc.
OTC: TCRG · Healthcare · Drug Manufacturers - General
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
8DFH 0DQ 12GM 21SS 16
v0.1 · 65/100 weight · provisional
↑ growth stability, market scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.8M
Employees
3
as of 2026-08-12
Market cap
$1.1M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$1.8M-$1.8M2025
Operating income-$1.7M-$1.7M2025
Total assets$140$1402025
Liabilities$235.4k$235.4k2025
Equity-$235.3k-$235.3k2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is The Cannaisseur Group, Inc.’s revenue?
The Cannaisseur Group, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Oncology Pharma Inc.——Aethlon Medical, Inc.42DBurzynski Research Institute, Inc.——Odyssey Health, Inc.21DAvalon GloboCare Corp.35DGenix Pharmaceuticals Corporation——Neighbors
Fulton →Key facts
CEOFloretta Gogo
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersAtlanta, GA
ExchangeOTC: TCRG
Employees3
IPO date2025-03-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.